Created in 2020, the BNEW (BNEW Barcelona) is a physical and digital B2B event focused on unique events to expand the new economy in Barcelona. Dr. Raúl Insa was invited to pitch at the Health panel entitled “New Generation Drugs; Innovation in a Pill” that  took place at  DFactory Barcelona last October  9th 2024. The…

Read More

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, is pleased to announce the database lock of the Phase 2b study SOMCT03 with SOM3355 for the treatment of chorea in Huntington’s Disease. Press Release

The Continuous Education Institute of the University of Barcelona (IL3) has invited Dr. Insa to lecture on drug repurposing in rare diseases. The event took place on July 10th in the summer university course titled “Rare diseases. From diagnostics to treatment” Course "Enfermedades raras. Del diagnóstico a la terapia" (ub.edu)

The current issue of The Brazilian Journal of Implantology and Health Sciences (Volume 6, Issue 6 (2024), Page 1040-105) cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G. Montgomery as Strategic Corporate Advisor to the Board.